+122.4%
TER vs MRNA
+153.9%
-31.5%
-58.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -10.0% | -2.2% | -7.8% | -9.9% |
| 7D | -17.9% | -12.7% | -5.2% | -17.4% |
| 30D | -40.7% | -20.7% | -20.1% | -40.1% |
| 3M | -46.5% | +46.3% | -92.8% | -47.4% |
| 6M | -40.5% | +305.2% | -345.7% | -50.6% |
| YTD | +5.9% | +561.2% | -555.3% | -24.2% |
| 1Y | +31.6% | +772.1% | -740.5% | -13.1% |
| 3Y | +122.4% | +147.0% | -24.6% | +74.3% |
| All | +122.4% | +153.9% | -31.5% | +74.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling